文献速递腹部MR

ECA与HBA增强MRI在LI-RADS非放疗TRA 2024中的诊断效能比较

Diagnostic Accuracy of Extracellular versus Hepatobiliary Contrast-enhanced MRI in LI-RADS Nonradiation Treatment Response Algorithm Version 2024.
PubMed 文献 · Radiology · 2026-01-01

本研究回顾性纳入216例肝癌局部区域治疗后接受肝移植患者,以移植肝病理为参考标准,比较ECA-MRI与HBA-MRI在LI-RADS非放疗TRA 2024中的诊断效能。不应用辅助征象时ECA-MRI对存活HCC的敏感度高于HBA-MRI;应用辅助征象后两组敏感度无显著差异。

要点

  • 不应用辅助征象时ECA-MRI对存活HCC的敏感度高于HBA-MRI,报告时需注意对比剂类型的影响。
  • 应用辅助征象后两种对比剂MRI敏感度相当,HBA-MRI提升更明显,建议常规结合辅助征象判读。
  • LI-RADS TRA Viable类别作为判定存活肿瘤的依据,其可靠性受MRI对比剂类型影响。

核心结论

  • 不应用辅助征象时,ECA-MRI检测存活HCC的敏感度显著高于HBA-MRI(74.0% vs 57.5%,P=.02)。
  • 应用辅助征象后两组敏感度相当(76.7% vs 67.1%,P=.16),辅助征象对HBA-MRI的提升更显著(P=.002)。

研究设计与样本

  • 回顾性研究,纳入2020年1月至2024年3月接受非放疗局部区域治疗后行肝移植的216例HCC患者,共414个治疗病灶。
  • 患者在肝移植前90天内接受ECA-MRI(77例)或HBA-MRI(139例)多期增强扫描,以移植肝病理为参考标准。
  • 两名放射科医师独立依据LI-RADS非放疗TRA 2024版进行分级,采用倾向性评分匹配,匹配后143对治疗病灶进入分析。
  • 用群聚自举重采样比较LI-RADS TRA Viable类别的敏感度、特异度和准确率,分不应用和应用辅助征象两种情况。

关键影像表现/征象

  • ECA-MRI在无辅助征象时Viable类别判定的敏感度为74.0%(54/73,95% CI:63.6-84.2),高于HBA-MRI的57.5%(42/73,95% CI:45.8-68.5)。
  • 应用辅助征象后ECA-MRI敏感度为76.7%(56/73,95% CI:66.7-86.3),HBA-MRI为67.1%(49/73,95% CI:56.0-77.5)。
  • 辅助征象对HBA-MRI的敏感度提升(57.5%提升至67.1%)较ECA-MRI(74.0%提升至76.7%)更显著。

诊断标准与关键数值

  • 不应用辅助征象时ECA-MRI检测存活HCC敏感度为74.0%(95% CI:63.6-84.2),HBA-MRI为57.5%(95% CI:45.8-68.5),P=.02。
  • 应用辅助征象后ECA-MRI敏感度为76.7%(95% CI:66.7-86.3),HBA-MRI为67.1%(95% CI:56.0-77.5),P=.16。
  • HBA-MRI应用辅助征象前后敏感度差异有统计学意义(P=.002),ECA-MRI无统计学意义(P=.25)。

临床应用与阅片要点

  • 使用HBA-MRI判读LI-RADS TRA时建议常规应用辅助征象以提高对存活HCC的检出敏感度。
  • 使用ECA-MRI判读LI-RADS TRA时Viable类别的敏感度基础较高,辅助征象的增量获益有限。
  • 报告LI-RADS TRA分级时应注明所用MRI对比剂类型,便于临床正确解读Viable类别的含义。

局限性

  • 回顾性单中心研究。
  • 接受HBA-MRI的患者多于ECA-MRI,虽经倾向性评分匹配仍可能存在未测混杂因素。
  • 两组患者MRI对比剂类型的选择可能受临床因素影响,存在选择性偏倚风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Whether the diagnostic accuracy of the Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm (TRA) differs according to the type of MRI contrast agent has been unclear. Purpose To compare the diagnostic accuracy of LI-RADS Nonradiation TRA version 2024 for detecting viable hepatocellular carcinoma (HCC) after locoregional therapy (LRT) using either extracellular contrast agent (ECA) MRI or hepatobiliary contrast agent (HBA) MRI. Materials and Methods This retrospective study included consecutive patients who underwent nonradiation LRT for HCC and liver transplant between January 2020 and March 2024. Patients underwent post-LRT multiphasic MRI using ECA or HBA within 90 days before transplant. Two radiologists independently assigned LI-RADS TRA categories in accordance with the LI-RADS Nonradiation TRA version 2024. Explant pathology served as the reference standard. Propensity score matching was conducted to balance the baseline characteristics between the two groups. After matching, the sensitivity, specificity, and accuracy of LI-RADS TRA Viable category-with and without ancillary features (AFs)-were compared between ECA MRI and HBA MRI using cluster bootstrap resampling. Results A total of 216 patients (mean age, 60 years ± 6.7 [SD]; 171 men; 77 underwent ECA MRI and 139 underwent HBA MRI) with 414 treated observations were included, and 143 matched pairs of treated observations were analyzed. Without AFs, ECA MRI showed higher sensitivity for helping detect viable HCC than HBA MRI (74.0% [54 of 73 observations; 95% CI: 63.6, 84.2] vs 57.5% [42 of 73 observations; 95% CI: 45.8, 68.5]; P = .02). With AFs, sensitivity improved for both contrast agents, with no evidence of a difference between groups (76.7% [56 of 73 observations; 95% CI: 66.7, 86.3] vs 67.1% [49 of 73 observations; 95% CI: 56.0, 77.5]; P = .16). The impact of AFs on sensitivity was more pronounced in HBA MRI (57.5% [42 of 73 observations; 95% CI: 45.8, 68.5] vs 67.1% [49 of 73 observations; 95% CI: 56.0, 77.5] with AFs; P = .002) than ECA MRI (74.0% [54 of 73 observations; 95% CI: 63.6, 84.2] vs 76.7% [56 of 73 observations; 95% CI: 66.7, 86.3] with AFs; P = .25). Conclusion ECA MRI demonstrated higher sensitivity than HBA MRI when AFs were not applied, whereas using AFs resulted in comparable sensitivities between groups. © RSNA, 2026 Supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Heo, Jung, Choi, et al. Diagnostic Accuracy of Extracellular versus Hepatobiliary Contrast-enhanced MRI in LI-RADS Nonradiation Treatment Response Algorithm Version 2024. Radiology. 2026. PMID: 42262242. doi:10.1148/radiol.253854

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。